Laurus Labs Ltd

NSE LAURUSLABS BSE 540222 lauruslabs.com

Q1 FY27, unaudited

Revenue: ₹2,026.31 Cr
Profit after tax: ₹362.07 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ crore	Q1 FY27	vs a year ago	FY26
Revenue from operations	2,026.31	+29.10%	6,812.90
Other income	9.18	−11.98%	54.95
Total income	2,035.49	+28.83%	6,867.85
Employee benefit expense	258.70	+20.44%	895.45
Finance costs	42.22	−18.02%	170.73
Depreciation & amortisation	123.87	+6.02%	480.05
Total expenses	1,554.13	+14.63%	5,685.97
Profit before tax	481.36	+114.68%	1,181.88
Tax expense	119.37	+89.06%	292.03
Profit after tax	362.07	+123.94%	890.14
Total comprehensive income	359.86	+123.56%	884.24

Earnings per share
Earnings per share, basic	₹6.81	₹16.47
Earnings per share, diluted	₹6.80	₹16.45

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Laurus Labs reported Q1 FY27 revenue of INR2,026 crores, a 29% year-on-year increase, driven by growth in the CDMO segment and continued strength in the affordable medicines portfolio. EBITDA margin expanded to 31.8% and profit after tax was around INR368 crores, with management describing this as the highest quarterly revenue, EBITDA and profit for the company. Management also discussed capex plans, the CDMO and Bio segment updates, and progress on new modalities including ADCs, peptides and gene therapy.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 53 published by the exchange

12 Aug 2026
Concall
Analyst / Investor Meet - Intimation
10 Aug 2026
Filing
Intimation Of ESG Score Given By NSE Sustainability Ratings And Analytics Limited
30 Jul 2026
Transcript
Earnings Call Transcript
27 Jul 2026
Filing
Allotment of ESOP / ESPS
25 Jul 2026
Filing
Update On Composite Scheme Of Arrangement
25 Jul 2026
Filing
Newspaper Publication
24 Jul 2026
Concall
Analyst / Investor Meet - Outcome
24 Jul 2026
Filing
Press Release / Media Release
24 Jul 2026
Presentation
Investor Presentation
24 Jul 2026
Filing
Change in Directorate
24 Jul 2026
Board meeting
Board Meeting Outcome for Outcome Of Board Meeting
24 Jul 2026
Results
Results - Financial Results For Quarter Ended 30.06.2026

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 12 Aug 2026.